Last reviewed · How we verify

Jason Lang, M.D., M.P.H. — Portfolio Competitive Intelligence Brief

Jason Lang, M.D., M.P.H. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
commercially available lansoprazole commercially available lansoprazole phase 3 Proton pump inhibitor H+/K+ ATPase Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AVM Biotechnology Inc · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. GBG Forschungs GmbH · 1 shared drug class
  4. HK inno.N Corporation · 1 shared drug class
  5. IBSA Institut Biochimique SA · 1 shared drug class
  6. Jun-Won Chung · 1 shared drug class
  7. Merck Sharp & Dohme LLC · 1 shared drug class
  8. Samsung Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jason Lang, M.D., M.P.H.:

Cite this brief

Drug Landscape (2026). Jason Lang, M.D., M.P.H. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jason-lang-m-d-m-p-h. Accessed 2026-05-18.

Related